Aradigm's AERx inhaler "safe" for interferon:
This article was originally published in Clinica
Executive Summary
In what is claimed to be the first human trial of interferon-alpha 2b inhalation, Aradigm says its AERx pulmonary drug delivery device was "safe and well tolerated" in healthy volunteers. The advantage of pulmonary delivery over conventional subcutaneous injection of interferon-alpha 2b is that it could reduce the dosage needed to achieve a therapeutic effect. This in turn may reduce adverse events, such as flu-like symptoms, that are associated with injection, says the Hayward, California firm.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.